Publications by authors named "Elodie Archier"

Background: Currently, treatment options for patients with advanced melanoma who experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest the antitumor activity of combined pembrolizumab and lenvatinib in patients with advanced melanoma progressing on immunotherapy. Herein, we report the clinical outcomes of combined lenvatinib and a programmed cell death protein-1 inhibitor (PD-1) in this population.

View Article and Find Full Text PDF
Article Synopsis
  • Cemiplimab has shown promise in real-world use for locally advanced and metastatic cutaneous squamous-cell carcinomas (CSCCs), with a best overall response rate of 50.4% among treated patients.
  • There was a median progression-free survival (PFS) of 7.9 months, and one-year overall survival (OS) was 73% for patients with better performance status (PS < 2).
  • Although some patients experienced severe adverse events, the overall safety and efficacy indicate cemiplimab may be a beneficial treatment option, especially for immunocompromised individuals.
View Article and Find Full Text PDF

Aim: In metastatic melanoma (MM) there is an agreement that a fast or slow progression should influence the choice between drugs with immediate impact (BRAF-inh) or delayed (ipilimumab) activity. MM kinetics thus appears crucial for medical decision, although only estimated through surrogate markers (tumour load or lactate dehydrogenase (LDH)). Our objective was to show that 1-MM kinetics can be measured and 2- is a real prognostic factor.

View Article and Find Full Text PDF